Pacific Biosciences Raises $200M in IPO | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Pacific Biosciences has gone public, raising $200 million through its initial public offering.

The Menlo Park, Calif.-based developer of single-molecule, real-time sequencing technology offered 12.5 million shares at $16 per share, the mid-point of its last estimated range of $15-$17. It expects to begin trading today on the Nasdaq under the ticker symbol "PACB."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: SNP reference panel from the Haplotype Reference Consortium, and more.

Halloran Consulting's Laurie Halloran lists at Stat News the mistakes she sees startup companies make when pursuing a clinical trial.

MIT researchers are using bees to collect and visualize urban microbiome samples, Wired reports.

Reliance on Excel leads to errors in gene name lists, a new Genome Biology paper reports.